Effectiveness of Premixed Bioactive Bioceramic MTA (Neo-Putty®) in Pulpotomies Primary Teeth

Hadassah Medical Center

Status: Active, not recruiting

Conditions: Pulpotomies on Primary Molars

Treatments: Other: Neo-Putty® as dressing agents in pulpotomized primary molars

Study type: Observational

Funder types: Other

Identifiers

NCT04962607

0994-20-HMO

Details and patient eligibility

About

The objective of this prospective randomized clinical trial is to assess clinically and radiographically, the effect of NeoPutty as a pulp medicament following coronal pulp amputation in human primary molars with carious pulp exposure in comparison to Formocresol (FC).

Enrollment: 50 patients

Sex: All

Ages: 2 to 10 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• primary teeth which requires pulpotomy.

Exclusion criteria

• not healthy patients,
• teeth which requires pulpectomy.

Trial design

50 participants in 2 patient groups

Study Group

Description:

1. Asymptomatic primary molars with deep carious lesions scheduled for regular treatment. 2. Exposure of a vital pulp due to caries. 3. No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract. 4. The possibility of proper restoration of the teeth.

Treatment:

Other: Neo-Putty® as dressing agents in pulpotomized primary molars

control group

Description:

1. Asymptomatic primary molars with deep carious lesions scheduled for regular treatment. 2. Exposure of a vital pulp due to caries. 3. No clinical or radiographic evidence of pulp degeneration, such as spontaneous pain, excessive bleeding from the root canal, internal root resorption, inter-radicular and/or periapical bone destruction, swelling, or sinus tract. 4. The possibility of proper restoration of the teeth.

Treatment:

Other: Neo-Putty® as dressing agents in pulpotomized primary molars